NCT04171622View on ClinicalTrials.gov

Lenvatinib and Pembrolizumab for the Treatment of Stage IVB Locally Advanced and Unresectable or Stage IVC Metastatic Anaplastic Thyroid Cancer

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

November 4, 2021

Primary Completion Date

August 31, 2027

Study Completion Date

August 31, 2027

Conditions
Metastatic Thyroid Gland CarcinomaPoorly Differentiated Thyroid Gland CarcinomaStage IVB Thyroid Gland Anaplastic Carcinoma AJCC v8Stage IVC Thyroid Gland Anaplastic Carcinoma AJCC v8Thyroid Gland Squamous Cell CarcinomaUnresectable Thyroid Gland Carcinoma
Interventions
DRUG

Lenvatinib

Given PO

BIOLOGICAL

Pembrolizumab

Given IV

Trial Locations (1)

77030

M D Anderson Cancer Center, Houston

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER